Ophthotech sets its sights on AMD

Ophthotech Corporation has announced deals with two companies to obtain the rights to treatments for age-related macular degeneration (AMD).

Ophthotech Corporation has announced deals with two companies to obtain the rights to treatments for age-related macular degeneration (AMD).

Ophthotech and Archemix have announced an exclusive, worldwide license agreement for the treatment of the wet and dry forms AMD. Under the terms of the agreement, Archemix has granted Ophthotec worldwide rights to all ophthalmic uses of the company's proprietary aptamers targeting the C5 component of the complement cascade.

Furthermore, Eyetech has also entered into an agreement with Ophthotech to divest its anti-platelet derived growth factor (PDGF) aptamer programme. Under the terms of this agreement, all rights to the programme will be transferred to Ophthotech, including rights to the preclinical compound E10030, in exchange for an up-front cash payment, an equity interest in Ophthotech and potential future milestones and royalties.

Ophthotech has so far raised $36 million, which it hopes will be sufficient to execute its AMD treatment strategy.

Related Videos
Fluid dynamics in wet macular degeneration: How fluid type affects visual acuity
EURETINA leadership discusses what to expect at the 2022 Congress, outlines Women in Retina programme
Paediatric eyes repair better with scleral buckling, adults need vitrectomy only for giant retinal tear-related detachments
Clinical trials in wet AMD: Impact of central subfield thickness, volatility on visual acuity
Post hoc analysis of Copernicus, Galileo trials find time since diagnosis affects BCVA outcomes in CRVO
Related Content
© 2023 MJH Life Sciences

All rights reserved.